<DOC>
	<DOC>NCT02998320</DOC>
	<brief_summary>This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks</brief_summary>
	<brief_title>Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis</brief_title>
	<detailed_description>This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide (E/C/F/TAF) for four Weeks. Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Cobicistat is a selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A subfamily. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue Ã f 2'-dexicytidine. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue).</detailed_description>
	<criteria>an age above 18 years consultation within 48 hours following a risk of HIV transmission (blood or sexual contact) indication for HIV postexposure prophylaxis (according to French guidelines) person able to understand the nature of the study person who signed his consent form to participate in the study person exposed to HIV risk from person infected by HIV, whose therapeutic history justifies the prescription of another combination of antiretroviral drugs contraindications to the prescription of Genvoy other medical contraindications person infected by hepatitis B virus pregnant or lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>